-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Head to Head Analysis: AIkido Pharma (NASDAQ:AIKI) and Data Knights Acquisition (NASDAQ:DKDCA)
Head to Head Analysis: AIkido Pharma (NASDAQ:AIKI) and Data Knights Acquisition (NASDAQ:DKDCA)
AIkido Pharma (NASDAQ:AIKI – Get Rating) and Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
Profitability
This table compares AIkido Pharma and Data Knights Acquisition's net margins, return on equity and return on assets.
Get AIkido Pharma alerts:Net Margins | Return on Equity | Return on Assets | |
AIkido Pharma | N/A | -10.81% | -10.12% |
Data Knights Acquisition | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings for AIkido Pharma and Data Knights Acquisition, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AIkido Pharma | 0 | 0 | 1 | 0 | 3.00 |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
Institutional and Insider Ownership
14.0% of AIkido Pharma shares are held by institutional investors. Comparatively, 97.3% of Data Knights Acquisition shares are held by institutional investors. 0.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
AIkido Pharma has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
Valuation & Earnings
This table compares AIkido Pharma and Data Knights Acquisition's top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AIkido Pharma | $10,000.00 | 3,473.51 | -$7.17 million | ($2.71) | -2.44 |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
Data Knights Acquisition has lower revenue, but higher earnings than AIkido Pharma.
Summary
AIkido Pharma beats Data Knights Acquisition on 5 of the 9 factors compared between the two stocks.
About AIkido Pharma
(Get Rating)
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
About Data Knights Acquisition
(Get Rating)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
AIkido Pharma (NASDAQ:AIKI – Get Rating) and Data Knights Acquisition (NASDAQ:DKDCA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.
合气道医药(纳斯达克:AIKI-GET评级)和数据骑士收购(纳斯达克:DKDCA-GET评级)都是小盘医疗公司,但哪一家更好?我们将根据这两家公司的机构所有权、分析师建议、估值、盈利能力、风险、股息和收益来比较它们的实力。
Profitability
盈利能力
This table compares AIkido Pharma and Data Knights Acquisition's net margins, return on equity and return on assets.
此表比较了合气道医药和数据骑士收购的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
AIkido Pharma | N/A | -10.81% | -10.12% |
Data Knights Acquisition | N/A | N/A | N/A |
净利润率 | 股本回报率 | 资产回报率 | |
合气道药业 | 不适用 | -10.81% | -10.12% |
数据骑士收购 | 不适用 | 不适用 | 不适用 |
Analyst Ratings
分析师评级
This is a breakdown of current ratings for AIkido Pharma and Data Knights Acquisition, as provided by MarketBeat.
这是MarketBeat提供的合气道医药和数据骑士收购的当前评级细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
AIkido Pharma | 0 | 0 | 1 | 0 | 3.00 |
Data Knights Acquisition | 0 | 0 | 0 | 0 | N/A |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
合气道药业 | 0 | 0 | 1 | 0 | 3.00 |
数据骑士收购 | 0 | 0 | 0 | 0 | 不适用 |
Institutional and Insider Ownership
机构和内部人持股
14.0% of AIkido Pharma shares are held by institutional investors. Comparatively, 97.3% of Data Knights Acquisition shares are held by institutional investors. 0.6% of AIkido Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
合气道医药14.0%的股份由机构投资者持有。相比之下,97.3%的数据骑士收购股份由机构投资者持有。合气道医药0.6%的股份由内部人士持有。强大的机构持股表明,捐赠基金、大型基金管理公司和对冲基金相信,一只股票有望实现长期增长。
Risk and Volatility
风险和波动性
AIkido Pharma has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Data Knights Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.
合气道医药的贝塔系数为1.33,这意味着其股价的波动性比标准普尔500指数高出33%。相比之下,数据骑士收购的贝塔系数为-0.01,这意味着其股价的波动性比标准普尔500指数低101%。
Valuation & Earnings
估值与收益
This table compares AIkido Pharma and Data Knights Acquisition's top-line revenue, earnings per share (EPS) and valuation.
此表比较了合气道医药和数据骑士收购的营收、每股收益(EPS)和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
AIkido Pharma | $10,000.00 | 3,473.51 | -$7.17 million | ($2.71) | -2.44 |
Data Knights Acquisition | N/A | N/A | $5.14 million | N/A | N/A |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
合气道药业 | $10,000.00 | 3,473.51 | -717万元 | ($2.71) | -2.44 |
数据骑士收购 | 不适用 | 不适用 | 514万美元 | 不适用 | 不适用 |
Data Knights Acquisition has lower revenue, but higher earnings than AIkido Pharma.
数据骑士收购的收入低于合气道医药,但收益高于合气道制药。
Summary
摘要
AIkido Pharma beats Data Knights Acquisition on 5 of the 9 factors compared between the two stocks.
合气道医药在两只股票比较的9个因素中有5个击败了数据骑士收购。
About AIkido Pharma
关于合气道药业
(Get Rating)
(获取评级)
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.
合气道制药公司是一家生物技术公司,专注于开发小分子抗癌疗法。该公司的治疗流水线包括前列腺癌、胰腺癌、急性髓系白血病(AML)和急性淋巴细胞白血病的治疗。它正在开发DHA-DFDC,一种胰腺候选药物;以及KPC34,一种治疗急性髓系白血病和急性淋巴细胞白血病的小分子药物。该公司还在开发一种抗病毒平台,可以抑制流感病毒、埃博拉病毒和马尔堡病毒、SARS-CoV、MERS-CoV和SARS-CoV-2等病毒的复制。它与德克萨斯大学、马里兰大学巴尔的摩分校、Silo Pharma Inc.和维克森林大学健康科学公司签署了许可协议。该公司前身为Spherix Inc.,并于2021年3月更名为合气道制药公司。合气道药业股份有限公司成立于1967年,总部设在纽约。
About Data Knights Acquisition
关于数据骑士的收购
(Get Rating)
(获取评级)
Data Knights Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the data centers and internet technology sectors. The company was incorporated in 2021 and is based in Chessington, the United Kingdom.
数据骑士收购公司没有重要的业务。它打算与数据中心和互联网技术领域的一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的业务合并。该公司成立于2021年,总部设在英国切辛顿。
Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受合气道药学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对合气道制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧